NUST Institutions Library Catalogue

Depression is a common neuropsychiatric condition, characterized by behavioral deficiencies,
mood swings, and cognitive impairments. Although fluoxetine is still a commonly prescribed
antidepressant, its drawbacks, including systemic side effects and delayed therapeutic results,
make it necessary to look at alternative treatments. Using a chronic restraint stress mouse model,
this study examines the effectiveness of 40 Hz light flicker therapy as a novel, non-invasive
neuromodulatory treatment for depression by directly contrasting it with fluoxetine treatment.
Behavioral tests such as the Light-Dark Box, Forced Swim, and Sucrose Preference tests showed
that 40 Hz light stimulation dramatically reduced depressive-like behaviors, frequently
outperforming the effects of fluoxetine. Histopathological examinations showed that parvalbuminexpressing interneurons, which are necessary for gamma oscillatory activity and inhibitory
circuitry, had been protected in the prefrontal cortex (PFC) and hippocampal regions. Increased
expression of brain-derived neurotrophic factor (BDNF) and parvalbumin (PV) was further
validated by molecular experiments, suggesting improved interneuron integrity and
neuroplasticity. These results demonstrate that 40 Hz light flicker therapy facilitates the functional
restoration of brain regions damaged in depression, pointing to distinct mechanisms from those of
traditional medication. Subsequent research endeavors ought to concentrate on refining
stimulation parameters, evaluating long-term safety and effectiveness, and clarifying
electrophysiological mechanisms via supplementary imaging and neurophysiological studies.
Promising translational potential is indicated by ongoing clinical investigations. To conclude, 40
Hz light flicker therapy might prove to be a useful supplement or substitute therapy, providing a
customized, side-effect-free choice for managing depression.